Works matching AU Rosenstock, Julio

Results: 311
    1
    2

    Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.

    Published in:
    Clinical Kidney Journal, 2021, v. 14, n. 9, p. 2136, doi. 10.1093/ckj/sfab104
    By:
    • Wanner, Christoph;
    • Cooper, Mark E;
    • Johansen, Odd Erik;
    • Toto, Robert;
    • Rosenstock, Julio;
    • McGuire, Darren K;
    • Kahn, Steven E;
    • Pfarr, Egon;
    • Schnaidt, Sven;
    • Eynatten, Maximilian von;
    • George, Jyothis T;
    • Gollop, Nicholas D;
    • Marx, Nikolaus;
    • Alexander, John H;
    • Zinman, Bernard;
    • Perkovic, Vlado
    Publication type:
    Article
    3

    Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.

    Published in:
    Clinical Kidney Journal, 2021, v. 14, p. 226, doi. 10.1093/ckj/sfaa225
    By:
    • Wanner, Christoph;
    • Cooper, Mark E;
    • Johansen, Odd Erik;
    • Toto, Robert;
    • Rosenstock, Julio;
    • McGuire, Darren K;
    • Kahn, Steven E;
    • Pfarr, Egon;
    • Schnaidt, Sven;
    • Eynatten, Maximilian von;
    • George, Jyothis T;
    • Gollop, Nicholas D;
    • Marx, Nikolaus;
    • Alexander, John H;
    • Zinman, Bernard;
    • Perkovic, Vlado;
    • investigators, the CARMELINA
    Publication type:
    Article
    4
    5

    85-LB: RESULTADOS DE LA MCG Y DE LA DURACION DE HIPOGLUCEMIA CON INSULINA ICODEC UNA VEZ A LA SEMANA VS. INSULINA GLARGINA U100 UNA VEZ AL DÍA EN PACIENTES CON T2D NO TRATADA CON INSULINA-ONWARDS 1 UN ANÁLISIS EXPLORATORIO.

    Published in:
    Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2023, v. 10, p. 19
    By:
    • Lorena, Ruiz Padilla Claudia;
    • Cristal, Díaz Cruz;
    • Bergenstal, Richard M.;
    • Watt, Sara K.;
    • Matos, Ana Laura S. A.;
    • Lingvay, Ildiko;
    • Mader, Julia K.;
    • Nishida, Tomoyuki;
    • Rosenstock, Julio
    Publication type:
    Article
    6

    INSULINA ICODEC UNA VEZ A LA SEMANA VS INSULINA GLARGINA U100 UNA VEZ AL DÍA EN COMBINACIÓN CON BOLOS DE INSULINA EN INDIVIDUOS CON DIABETES TIPO 2 EN RÉGIMEN BASAL-BOLO (ONWARS 4).

    Published in:
    Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2023, v. 10, p. 22
    By:
    • Pedro Alberto, García Hernández;
    • Brisa, Castro Sánchez;
    • Mathieu, Chantal;
    • Ásbjörnsdóttir, Björg;
    • Bajaj, Harpreet S.;
    • Lane, Wendy;
    • Laura Matos, Ana;
    • Murthy, Sreenivasa;
    • Stachlewska, Karolina;
    • Rosenstock, Julio
    Publication type:
    Article
    7

    MEJORA DE LA A1C Y DEL TIEMPO EN RANGO (TER) CON LA INSULINA SEMANAL ICODEC CONTRA LA INSULINA GLAGINA U100 EN PACIENTES CON DIABETES TIPO 2 SIN USO PREVIO DE INSULINA - ONWARDS-1.

    Published in:
    Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2023, v. 10, p. 21
    By:
    • Emmanuel Marin, Valdez Solis;
    • Erika, Yokoyama Madokoro Megumi;
    • Rosenstock, Julio;
    • Bain, Stephen C.;
    • Gowda, Amoolya;
    • Horio, Hiroshi;
    • Jodar, Esteban;
    • Lehrskov, Lars;
    • Lingvay, Ildiko;
    • Trevisan, Roberto;
    • Mosenzon, Ofri
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1221, doi. 10.1111/dom.14354
    By:
    • McCrimmon, Rory J.;
    • Al Sifri, Saud;
    • Emral, Rifat;
    • Mohan, Viswanathan;
    • Sauque‐Reyna, Leobardo;
    • Trescolí, Carlos;
    • Lalic, Nebojsa;
    • Alvarez, Agustina;
    • Demil, Nacima;
    • Coudert, Mathieu;
    • Shaunik, Alka;
    • Bonnemaire, Mireille;
    • Rosenstock, Julio
    Publication type:
    Article
    32
    33

    Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
    By:
    • Espeland, Mark A.;
    • Pratley, Richard E.;
    • Rosenstock, Julio;
    • Kadowaki, Takashi;
    • Seino, Yutaka;
    • Zinman, Bernard;
    • Marx, Nikolaus;
    • McGuire, Darren K.;
    • Andersen, Knut Robert;
    • Mattheus, Michaela;
    • Keller, Annett;
    • Weber, Maria;
    • Johansen, Odd Erik
    Publication type:
    Article
    34
    35
    36

    Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1567, doi. 10.1111/dom.14068
    By:
    • Del Prato, Stefano;
    • Frias, Juan Pablo;
    • Blonde, Lawrence;
    • Aroda, Vanita R.;
    • Shehadeh, Niam;
    • Saremi, Aramesh;
    • Dex, Terry;
    • Niemoeller, Elisabeth;
    • Souhami, Elisabeth;
    • Liu, Minzhi;
    • Rosenstock, Julio
    Publication type:
    Article
    37
    38
    39

    Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1062, doi. 10.1111/dom.13995
    By:
    • Cooper, Mark E.;
    • Rosenstock, Julio;
    • Kadowaki, Takashi;
    • Seino, Yutaka;
    • Wanner, Christoph;
    • Schnaidt, Sven;
    • Clark, Douglas;
    • Johansen, Odd Erik
    Publication type:
    Article
    40

    Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 427, doi. 10.1111/dom.13945
    By:
    • Perkins, Bruce A.;
    • Soleymanlou, Nima;
    • Rosenstock, Julio;
    • Skyler, Jay S.;
    • Laffel, Lori M.;
    • Liesenfeld, Karl‐Heinz;
    • Neubacher, Dietmar;
    • Riggs, Matthew M.;
    • Johnston, Curtis K.;
    • Eudy‐Byrne, Rena J.;
    • Elmokadem, Ahmed;
    • George, Jyothis T.;
    • Marquard, Jan;
    • Nock, Valerie
    Publication type:
    Article
    41
    42

    Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
    By:
    • Aroda, Vanita R.;
    • Capehorn, Matthew S.;
    • Chaykin, Louis;
    • Frias, Juan P.;
    • Lausvig, Nanna L.;
    • Macura, Stanislava;
    • Lüdemann, Jörg;
    • Madsbad, Sten;
    • Rosenstock, Julio;
    • Tabak, Omur;
    • Tadayon, Sayeh;
    • Bain, Stephen C.
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50